ATAI Life Sciences is trading 45.1% up today at $7.79 following reports that Eli Lilly is in advanced talks to acquire AtaiBeckley, a psychedelic drug developer closely linked to the company.
- The potential premium takeover could be announced as early as this week, significantly boosting investor optimism regarding the sector.
- The move highlights the strategic value of ATAI Life Sciences' psychedelic drug portfolio and its competitive positioning in the neuroscience market.